BNET Industries
Tiens Biotech Group USA Inc. (TBV) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $54.9M
- Profit
- Dec 31 2007
- $18.5M
- Market Cap
- Aug 27 2008
- $89.5M
Latest News and Analysis
Tiens Biotech Group Reports First Quarter Results
NEW YORK, May 15 /Xinhua-PRNewswire/ -- Tiens Biotech Group USA, Inc. (the ''Company'' or ''Tiens''), , http://www.tiens-bio.com/ , announced financial results for the first quarter ended March 31, 2008. Revenue for the first quarter of 2008 was $12.8 million compared to $16.2 million for the first quarter of...
Fourth Quarter Results Spark Interest: Sector Specific.
M2 PRESSWIRE-12 April 2007-Pinnacle Digest: Fourth Quarter Results Spark Interest: Sector SpecificC1994-2007 M2 COMMUNICATIONS LTD RDATE:12042007 To read this article in its entirety, visit www.pinnacledigest.com. Tiens Biotech Group USA, Inc. (AMEX: TBV) experienced a marginal decrease in share value...
TheCapitalReport.com Issues Update on (AMEX: TBV)
TheCapitalReport.com issuesa trader's update on Tiens Biotech Group USA, Inc. (AMEX: TBV) after www.buyins.net initiates coverage releasing thelatest TBV short sale data through July 27, 2006. To view the release in it’s entirety, go to: http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Cmt%5C2006%5C07%5C27%5C81296734.html%26clientid%3D168%26provider%3DM2_COMMUNICATIONS&symbol=TBV Please visit http://www.TheCapitalReport.com for a TBVprofile. TheCapitalReport.com is an...
Tiens Biotech Group USA Inc. (TBV) SqueezeTrigger Price is $5.17. Approximately 1.9 million Shares Shorted Since April 2005 According To Buyins.net Research Report.
M2 PRESSWIRE-27 July 2006-BUYINS.NET: Tiens Biotech Group USA Inc. TBV SqueezeTrigger Price is $5.17. Approximately 1.9 million Shares Shorted Since April 2005 According To Buyins.net Research ReportC1994-2006 M2 COMMUNICATIONS LTD RDATE:27072006 www.buyins.net, is initiating coverage of Tiens Biotech Group...
TheCapitalReport.com Issues (AMEX: TBV) Trader's Alert
TheCapitalReport.com issues a trader'salert on Tiens Biotech Group USA, Inc. after the Association for InvestorAwareness AIA initiates coverage and rates TBV. To read the AIA reportin its entirety, please click the following link: http://www.investorawareness.org/pdf/aia_se_tiensbiotech.pdf . Please visit http://www.TheCapitalReport.com for a TBV profile, latestnews, and full disclosure. TheCapitalReport.com...
TheCapitalReport.com Issues Update on (AMEX: TBV)
TheCapitalReport.com issues a trader'supdate on Tiens Biotech Group USA, Inc. (AMEX: TBV). TBV is up $.41 or8% intraday after the company released news this morning regarding a firstquarter revenue increase of 17% and a net income rise of 20.8%. The releasestates that as of March 31, 2006, Tiens USA...
China Stocks to Watch for Wednesday, May 10, 2006.
M2 PRESSWIRE-10 May 2006-China Venture Forum: China Stocks to Watch for Wednesday, May 10, 2006C1994-2006 M2 COMMUNICATIONS LTD RDATE:10052006 Shanghai, China - China Venture Forum, a leading equity research newsletter of micro- and small-cap China Stocks, announced China stocks to watch...
TheSUBWAY.com Posts Stock Pick List: Both in China and the International Market!
TheSUBWAY.com names the following stocks to itsStock Pick List: Tiens Biotech Group, Inc. (AMEX: TBV), Dell (NASDAQ: DELL), InPhonic, Inc. (NASDAQ: INPC), Ness Technologies, Inc. (NASDAQ: NSTC). Tiens Biotech Group USA, Inc. (AMEX: TBV) has been rated "Outperform,"with a price target of $12.30 by Beacon Equity Research. The report isauthored...
Hot Stocks To Watch for Tuesday, May 9, 2006: Leading Nutritional Products Company!
TheSUBWAY.com announces the following stocks toits Hot Stocks List: Tiens Biotech Group, Inc. (AMEX: TBV), PacificEthanol, Inc. (NASDAQ: PEIX), Hansen Natural Corporation (NASDAQ: HANS),aQuantive, Inc. (NASDAQ: AQNT). Tiens Biotech Group USA, Inc. (AMEX: TBV) has been rated "Outperform,"with a price target of $12.30 by Beacon Equity Research. The report isauthored...
TIENS REPORTS NET INCOME INCREASED BY MORE THAN $7.6 MILLION.(Tiens Biotech Group (USA), Inc.)
Tiens Biotech Group USA, Inc. (BULLETIN BOARD: TBGU), which conducts its main business through its subsidiary Tianshi Biological Development Co., Ltd ("Tianshi China"), has announced that its financial results for the three months and six months ended June 30, 2004 as reported in...
- Next »
- page 1 of 1
- « Previous
- Incorporated: 1990
- CEO: Mr. Jinyuan Li
Tiens Biotech Group USA researches, develops, manufactures, and markets nutrition supplement products, including wellness products and dietary supplement products and personal care products. Co.'s operations are conducted from its headquarters in Tianjin, People's Republic of China (China) through its 80.0% owned subsidiary, Tianjin Tianshi Biological Development Co. Ltd. As of Dec 31 2006, Co. sold its products to affiliated companies in China and 63 countries internationally. Co. registered its products under the logo Tiens with the State Administration of Industry and Commerce in China.
Key Competitors
Tiens Biotech Group USA Inc. Company Info
Board of Directors
Mr. Jinyuan Li
Chairman
Mr. Wenjun Jiao
Mr. Yu Peng Yan
Dr. Socorro Maria Quintero
Mr. Howard R. Balloch
Mr. Gilbert D. Raker
Contact Information
No.6 Yuanquan Road
Wuqing Development Area
Tianjin New-Tech Industrial Park
Tianjin,
86 22 8213-7915
NAICS Code
Drugs and Druggists' Sundries Merchant Wholesalers: 424210
